Adalimumab (HUMIRA): a review - PubMed (original) (raw)

Affiliations

• PMID: 12884458

Review

Adalimumab (HUMIRA): a review

Noah Scheinfeld. J Drugs Dermatol. 2003 Aug.

Abstract

Adalimumab (HUMIRA, Abbott Laboratories) is a new fully human TNF-alpha monoclonal antibody recently approved for the treatment of rheumatoid arthritis and undergoing trials for use in treating other conditions, including psoriasis and psoriatic arthritis. This article reviews its mechanisms of action, clinical trial results, and related discussion.

PubMed Disclaimer

Similar articles

• Adalimumab (Humira): a brief review for dermatologists.
  Scheinfeld N. Scheinfeld N. J Dermatolog Treat. 2004 Dec;15(6):348-52. doi: 10.1080/09546630410017284. J Dermatolog Treat. 2004. PMID: 15764045 Review.
• Adalimumab (humira) for rheumatoid arthritis.
  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2003 Mar 31;45(1153):25-7. Med Lett Drugs Ther. 2003. PMID: 12663965 No abstract available.
• [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
  Hirohata S. Hirohata S. Nihon Rinsho. 2007 Jul;65(7):1202-8. Nihon Rinsho. 2007. PMID: 17642233 Review. Japanese.
• Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis.
  Patel T, Gordon KB. Patel T, et al. Dermatol Ther. 2004;17(5):427-31. doi: 10.1111/j.1396-0296.2004.04045.x. Dermatol Ther. 2004. PMID: 15379777 Review.
• Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
  Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Furst DE, et al. J Rheumatol. 2003 Dec;30(12):2563-71. J Rheumatol. 2003. PMID: 14719195 Clinical Trial.

Cited by

• Engineering a Novel Probiotic Toolkit in Escherichia coli Nissle 1917 for Sensing and Mitigating Gut Inflammatory Diseases.
  Weibel N, Curcio M, Schreiber A, Arriaga G, Mausy M, Mehdy J, Brüllmann L, Meyer A, Roth L, Flury T, Pecina V, Starlinger K, Dernič J, Jungfer K, Ackle F, Earp J, Hausmann M, Jinek M, Rogler G, Antunes Westmann C. Weibel N, et al. ACS Synth Biol. 2024 Aug 16;13(8):2376-2390. doi: 10.1021/acssynbio.4c00036. Epub 2024 Aug 8. ACS Synth Biol. 2024. PMID: 39115381 Free PMC article.
• Biologics and Biosimilars in Psoriasis.
  Ahmed SS, De A, Das S, Manchanda Y. Ahmed SS, et al. Indian J Dermatol. 2023 May-Jun;68(3):282-295. doi: 10.4103/ijd.ijd_421_23. Indian J Dermatol. 2023. PMID: 37529455 Free PMC article.
• An AAV-Based NF-κB-Targeting Gene Therapy (rAAV-DMP-miR533) to Inflammatory Diseases.
  Luo T, Wang Y, Tang H, Zhou F, Chen Y, Pei B, Wang J. Luo T, et al. J Inflamm Res. 2022 Jun 14;15:3447-3466. doi: 10.2147/JIR.S362732. eCollection 2022. J Inflamm Res. 2022. PMID: 35726215 Free PMC article.
• Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.
  Papasavvas I, Tugal-Tutkun I, Herbort CP Jr. Papasavvas I, et al. Pharmaceuticals (Basel). 2022 Mar 24;15(4):398. doi: 10.3390/ph15040398. Pharmaceuticals (Basel). 2022. PMID: 35455395 Free PMC article. Review.
• Diagnosis and Treatment of Primary Inflammatory Choriocapillaropathies (PICCPs): A Comprehensive Overview.
  Papasavvas I, Herbort CP Jr. Papasavvas I, et al. Medicina (Kaunas). 2022 Jan 21;58(2):165. doi: 10.3390/medicina58020165. Medicina (Kaunas). 2022. PMID: 35208488 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information